Get all premium features to the best stock analysis tool

RTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million. Meanwhile, the quarter-end stake value increased by $219.88 million, reflecting both trading and price appreciation.

Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading and share price movements.

Boone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter. As a result, the quarter-end position value decreased by $13.57 million.

Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.

WALTHAM, Mass. and BOULDER, Colo.

Sphera Funds bought 279,974 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $7.87 million. The quarter-end position value increased by $12.03 million, reflecting both new shares and stock price appreciation.

Cogent Biosciences, Inc. remains a Buy as bezuclastinib advances toward triple approval in GIST and systemic mastocytosis (advanced, non advanced). Bezuclastinib demonstrated strong efficacy in pivotal trials, with durable clinical benefit and superior symptom improvement versus competitors. COGT's robust cash position ($900.8m) supports its path to commercialization, despite significant R&D-driven losses and competitive risks.